ATE197038T1 - N-aroyl-glycin-hydroxamsäure-derivate und verwandte verbindungen - Google Patents

N-aroyl-glycin-hydroxamsäure-derivate und verwandte verbindungen

Info

Publication number
ATE197038T1
ATE197038T1 AT96911095T AT96911095T ATE197038T1 AT E197038 T1 ATE197038 T1 AT E197038T1 AT 96911095 T AT96911095 T AT 96911095T AT 96911095 T AT96911095 T AT 96911095T AT E197038 T1 ATE197038 T1 AT E197038T1
Authority
AT
Austria
Prior art keywords
aroyl
acid derivatives
related compounds
hydroxamic acid
glycine hydroxamic
Prior art date
Application number
AT96911095T
Other languages
English (en)
Inventor
Edward F Kleinman
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE197038T1 publication Critical patent/ATE197038T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
AT96911095T 1995-07-26 1996-05-14 N-aroyl-glycin-hydroxamsäure-derivate und verwandte verbindungen ATE197038T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US152495P 1995-07-26 1995-07-26
PCT/IB1996/000451 WO1997005105A1 (en) 1995-07-26 1996-05-14 N-(aroyl)glycine hydroxamic acid derivatives and related compounds

Publications (1)

Publication Number Publication Date
ATE197038T1 true ATE197038T1 (de) 2000-11-15

Family

ID=21696482

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96911095T ATE197038T1 (de) 1995-07-26 1996-05-14 N-aroyl-glycin-hydroxamsäure-derivate und verwandte verbindungen

Country Status (20)

Country Link
US (2) US6225351B1 (de)
EP (1) EP0850215B1 (de)
JP (1) JP3131225B2 (de)
KR (1) KR100332273B1 (de)
CN (1) CN1090614C (de)
AT (1) ATE197038T1 (de)
AU (1) AU711755B2 (de)
CA (1) CA2227237C (de)
DE (1) DE69610709T2 (de)
DK (1) DK0850215T3 (de)
ES (1) ES2151156T3 (de)
GR (1) GR3034969T3 (de)
IL (1) IL118889A (de)
MX (1) MX9800710A (de)
NO (1) NO310230B1 (de)
NZ (1) NZ305940A (de)
PT (1) PT850215E (de)
TW (1) TW401389B (de)
WO (1) WO1997005105A1 (de)
ZA (1) ZA966314B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5801195A (en) 1994-12-30 1998-09-01 Celgene Corporation Immunotherapeutic aryl amides
US5728845A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic nitriles
KR19990001101A (ko) * 1997-06-12 1999-01-15 손경식 캐테콜 아미노산 유도체, 이의 제조방법 및 그를 함유한 약제 조성물
ES2196592T3 (es) 1997-07-31 2003-12-16 Celgene Corp Acidos alcanohidroxamicos sustituidos y metodo para reducir el nivel de tnf-alfa.
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
PL200923B1 (pl) 1999-08-21 2009-02-27 Nycomed Gmbh Lek zawierający inhibitor PDE w połączeniu z agonistą receptoraß₂ -adrenergicznego oraz zastosowanie połączenia roflumilastu i salmeterolu
US6667316B1 (en) 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
US6699899B1 (en) 1999-12-21 2004-03-02 Celgene Corporation Substituted acylhydroxamic acids and method of reducing TNFα levels
US6326388B1 (en) 1999-12-21 2001-12-04 Celgene Corporation Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
US8030343B2 (en) 2000-06-08 2011-10-04 Celgene Corporation Pharmaceutically active isoindoline derivatives
IT1317049B1 (it) * 2000-06-23 2003-05-26 Sigma Tau Ind Farmaceuti Composti utili per la preparazione di medicamenti ad attivita'inibitrice della fosfodiesterasi iv.
CA2492035A1 (en) * 2002-07-11 2004-01-15 Vicuron Pharmaceuticals, Inc. N-hydroxyamide derivatives possessing antibacterial activity
ES2387803T3 (es) * 2003-01-08 2012-10-02 Novartis Vaccines And Diagnostics, Inc. Agentes antibacterianos
JP2006522151A (ja) 2003-04-01 2006-09-28 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 不妊症におけるホスホジエステラーゼ阻害剤
US7244759B2 (en) 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
EP2258357A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
EP2275096A3 (de) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenese durch modulation des Muscarinrezeptors
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (de) 2005-10-31 2011-04-27 Braincells, Inc. Gaba-rezeptor-vermittelte modulation von neurogenese
JP2009520695A (ja) * 2005-12-15 2009-05-28 ヴィキュロン ファーマシューティカルズ インコーポレイテッド 抗菌活性を有するｎ−ヒドロキシアミド誘導体
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (de) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenese mittels angiotensin-modulation
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CA2691987C (en) 2007-06-12 2016-08-16 Achaogen, Inc. Antibacterial agents
KR101861025B1 (ko) * 2008-01-08 2018-05-24 랜티우스 메디컬 이메징, 인크. 영상화 제제로서의 ｎ-알콕시아미드 접합체
EP2196465A1 (de) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea-Derivate als PDE4 Hemmern
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2226323A1 (de) 2009-02-27 2010-09-08 Almirall, S.A. Neuartige Tetrahydropyrazol[3,4-c]isochinolin-5-amin-Derivate
EP2380890A1 (de) 2010-04-23 2011-10-26 Almirall, S.A. Neue 7,8-Dihydro-1,6-Naphthyridin-5(6H)-on-Derivate als PDE4 Inhibitoren
EP2394998A1 (de) 2010-05-31 2011-12-14 Almirall, S.A. 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl Derivate als PDE4 Inhibitoren
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2013170165A1 (en) 2012-05-10 2013-11-14 Achaogen, Inc. Antibacterial agents
CN108821999A (zh) * 2018-04-26 2018-11-16 南昌大学 一种氨基酸异羟肟酸类氨肽酶n抑制剂及制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3732295A (en) * 1969-11-25 1973-05-08 Dompe Farmaceutici Spa Trimethoxybenzoyl-aminoalkanoic acids
US3692827A (en) * 1970-06-26 1972-09-19 Inst Chemioterapico Italiano S Derivatives of aminoalkanoic acids
GB1418595A (en) * 1973-02-14 1975-12-24 Ss Pharmaceutical Co N- 2-alkoxybenzoyl- amino acids and a process for producing the same
US4193926A (en) 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
US4728670A (en) 1986-06-04 1988-03-01 E. R. Squibb & Sons, Inc. Biphenyl hydroxamic acids
CA1316935C (en) 1987-12-09 1993-04-27 Hiromitsu Saito Hydroxamic acid derivatives
DE3823299A1 (de) 1988-07-07 1990-01-11 Schering Ag Substituierte phenyl-pyrrolidin-2-one, -oxazolidin-2-one und -imidazolidin-2-one, ihre herstellung sowie verwendung in arzneimitteln
US5068251A (en) 1988-12-16 1991-11-26 Abbott Laboratories Lipoxygenase inhibiting compounds
KR900016822A (ko) 1990-04-20 1990-11-14 하라 레이노스께 슬라이드 프로젝터
US5124455A (en) 1990-08-08 1992-06-23 American Home Products Corporation Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents
FR2669029B1 (fr) 1990-11-14 1994-09-02 Adir Nouveaux derives de la n-benzoyl proline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
CA2114114C (en) 1992-06-15 2005-05-03 Nigel Robert Arnold Beeley Trisubstituted phenyl derivatives as selective phosphodiesterase iv inhibitors
IL106517A0 (en) 1992-07-28 1994-08-26 Rhone Poulenc Rorer Ltd Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic or heteroatom containing linking group
US5298652A (en) 1992-12-08 1994-03-29 Hoffmann-La Roche Inc. N-substituted glycines, inhibitors of phospholipase A2
WO1995006032A1 (fr) * 1993-08-20 1995-03-02 Banyu Pharmaceutical Co., Ltd. Inhibiteur de la tyrosine kinase

Also Published As

Publication number Publication date
PT850215E (pt) 2001-03-30
DE69610709T2 (de) 2001-02-22
NZ305940A (en) 1999-05-28
EP0850215B1 (de) 2000-10-18
NO310230B1 (no) 2001-06-11
ZA966314B (en) 1998-01-26
NO980313D0 (no) 1998-01-23
AU711755B2 (en) 1999-10-21
JP3131225B2 (ja) 2001-01-31
IL118889A0 (en) 1996-10-31
GR3034969T3 (en) 2001-02-28
ES2151156T3 (es) 2000-12-16
KR19990035870A (ko) 1999-05-25
JPH10511695A (ja) 1998-11-10
CN1090614C (zh) 2002-09-11
US6225351B1 (en) 2001-05-01
MX9800710A (es) 1998-04-30
EP0850215A1 (de) 1998-07-01
DE69610709D1 (de) 2000-11-23
IL118889A (en) 2003-12-10
US6384236B1 (en) 2002-05-07
WO1997005105A1 (en) 1997-02-13
KR100332273B1 (ko) 2002-06-20
CA2227237A1 (en) 1997-02-13
DK0850215T3 (da) 2000-11-20
US20020055543A1 (en) 2002-05-09
TW401389B (en) 2000-08-11
CA2227237C (en) 2005-12-13
AU5407996A (en) 1997-02-26
HK1018047A1 (en) 1999-12-10
NO980313L (no) 1998-03-23
CN1192201A (zh) 1998-09-02

Similar Documents

Publication Publication Date Title
DE69610709D1 (de) N-aroyl-glycin-hydroxamsäure-derivate und verwandte verbindungen
MX9804793A (es) Acidos arilsulfonamido-hidroxamicos alfa-sustituidos como inhibidores de factor de necrosis tumoral-alfa y de metaloproteinasa de matriz.
DK0738270T3 (da) Dihydropyrazolopyrroler
CA2216796A1 (en) Quinazoline derivatives
NZ514487A (en) Carbamic acid derivatives and their use as metabotropic glutamate receptor ligands
NO304793B1 (no) nor-gallesyrederivater, og anvendelse av dem for fremstilling av legemiddel
FI942075A0 (fi) Sappihappojohdannaisten tetratsolijohdannaisia, menetelmä niiden valmistamiseksi ja näiden yhdisteiden käyttö lääkeaineina
AP9701041A0 (en) Pyridylpyrrole compounds.
NZ508268A (en) Bicyclic pyrimidines and bicyclic 3,4- dihydropyrimidines as inhibitors of cellular proliferation
DE60315674D1 (de) Neue imidazopyridine und ihre verwendung
GEP20022678B (en) Bicyclic Heteroaromatic Compounds As Protein Tyrosine Kinase Inhibitors, their Pharmaceutical compositions and methods for Treatment
GEP20033140B (en) Substituted Bicyclic Derivatives Useful as Anticancer Agents
EA200501009A1 (ru) Замещённые пирролопиразольные производные в качестве ингибиторов киназы
DE60305514D1 (de) Neue verwendung von benzothiazolderivaten
ATE102930T1 (de) Heterozyklische verbindungen, deren herstellung und medikamente diese enthaltend.
BG103219A (bg) Бензамидинови производни и използването им като лекарствени средства с ltb4-антагонистично действие
DE69904483D1 (de) Nitrat-salze als arzneimittel
DE69429591D1 (de) Therapeutisch wirksame Verbindungen
TR199801840A2 (xx) Yeni imidazolidin t�revleri ve bunlar� i�eren farmakolojik preparatlar.
EA200400208A1 (ru) Фенилацетамидотиазольные производные, способ их получения и их использования в качестве противоопухолевых средств
ATE114154T1 (de) Thienotriazolodiazepine und ihre pharmazeutische verwendung.
HUT45081A (en) Process for producing amino acid derivatives and pharmaceuticals comprising these compounds as active ingredient
ATE115558T1 (de) Harnstoffderivate, deren herstellung sowie diese enthaltende pharmazeutische zusammensetzungen.
NZ231293A (en) 1,2,3,4-tetrahydro-1,9-acridinediamines, homologues thereof, and pharmaceutical compositions
HUT71127A (en) 2,3,4,5-tetrahydro-1h-3-benzodiazepines and pharmaceutically acceptable acid additional salts thereof, pharmaceutical compositions containing them and process for their preparation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee